Eyenovia congratulates Formosa Pharmaceuticals on FDA approval

Eyenovia congratulates Formosa Pharmaceuticals on the FDA approval of clobetasol propionate ophthalmic suspension 0.05% for the treatment of post-operative inflammation and pain following ocular surgery. Eyenovia acquired the U.S. commercial rights to clobetasol propionate ophthalmic suspension 0.05% from Formosa Pharmaceuticals in August 2023. “We congratulate Formosa Pharmaceuticals on the FDA approval of clobetasol propionate ophthalmic suspension 0.05%, the first approved therapeutic to leverage its APNT formulation platform, and the first new ophthalmic steroid to enter the U.S. market in over 15 years,” stated Michael Rowe, Eyenovia’s Chief Executive Officer. “The efficacy profile of clobetasol propionate ophthalmic suspension 0.05% is highly desirable, and adverse events were seen in no more than 2% of patients; many of the adverse events may have been caused by the surgical procedure itself.”